Skip to content
CancerIndex

Publication

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Authors not recorded

N Engl J Med2000PMID 11070098stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
11070098
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
MGMT Promoter Methylation3
(prognostic)GlioblastomaCURATED_BROADERPrognosticBSupports Better Outcome4accepted
EID172

MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.

PMID 11070098 · Esteller et al., 2000 · Open in CIViC

civic
CarmustineGlioblastomaCURATED_BROADERPredictiveBSupports Sensitivity Response4accepted
EID308

MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells.

PMID 11070098 · Esteller et al., 2000 · Open in CIViC

civic
O6-BenzylguanineGlioblastomaCURATED_BROADERPredictiveESupports Sensitivity Response4accepted
EID309

In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with init… (full text at CIViC)

PMID 11070098 · Esteller et al., 2000 · Open in CIViC

civic